Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs KLA Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.12 (market cap $8.04B), while KLA Corp. trades at $223.75 (market cap $300.93B). The key difference: KLA Corp. is far larger — about 37.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and KLA Corp. pays a 0.4% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KLAC | |
|---|---|---|
Market Cap | $8.04B | $300.93B |
Sector | Health | Technology |
52-Week High | $339.75 | $301.71 |
52-Week Low | $241.71 | $84.39 |
Enterprise Value | $7.85B | $302.11B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
KLA Corporation (KLAC) trades at $222.25, down 4.0% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation multiples remain elevated. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.
Outlook remains supported by AI-driven semiconductor equipment demand and consistent earnings beats, but rich valuation and competitive pressures pose risks. Analyst consensus is bullish with a $239.86 price target, suggesting potential upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
